GlassScriptPhysician profile
David Howard Mendelson
NPI 1124018833
$2,330.56
in general payments reported to CMS, 2019-2025
27 companies · $768 in 2025
The $768 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2020: $157 · 2021: $266 · 2022: $432 · 2023: $210 · 2024: $98.93 · 2025: $768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $554 · Travel and Lodging: $389 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $553.67 |
| Travel and Lodging | $389.32 |
| Education | $134.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $780.53 | 2022-2025 | Oxford, Oxford Partial Knee |
| Stryker Corporation | $304.22 | 2023-2025 | Actishield, Blueprint Patient Specific Instrumentation |
| Nuvasive Specialized Orthopedics, INC. | $189.19 | 2019 | |
| Abbvie INC. | $170.18 | 2019-2023 | |
| Amgen INC. | $167.47 | 2019-2024 | |
| Bioness INC | $155.02 | 2021 | |
| Janssen Biotech, INC. | $70.66 | 2020-2022 | |
| Si-Bone, INC. | $69.95 | 2020 | |
| Endo Pharmaceuticals INC. | $61.07 | 2019-2021 | |
| Treace Medical Concepts, INC. | $60.79 | 2025 | |
| Alexion Pharmaceuticals, INC. | $26.20 | 2025 | Strensiq |
| Horizon Therapeutics Plc | $25.87 | 2020 | |
| Convatec INC. | $22.10 | 2023 | |
| Kci USA, INC. | $21.51 | 2019 | |
| Boston Scientific Corporation | $21.19 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heron Therapeutics, INC. | $20.34 | 2022 | |
| Pinnacle, INC | $19.55 | 2024 | |
| Bioventus LLC | $17.15 | 2021 | |
| Osteomed LLC | $15.94 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.69 | 2022 | |
| Ucb, INC. | $14.39 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.31 | 2022 | |
| Linvatec Corporation | $14.09 | 2022 | |
| Depuy Synthes Sales INC. | $14.03 | 2024 | Orthovisc, Monovisc |
| Nalu Medical, INC. | $13.82 | 2025 | Nalu Neurostimulation System |
| Radius Health, INC. | $13.14 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $12.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mendelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.